Literature DB >> 33622719

Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption.

Leila B Giron1, Emmanouil Papasavvas1, Xiangfan Yin1, Aaron R Goldman1, Hsin-Yao Tang1, Clovis S Palmer2,3, Alan L Landay4, Jonathan Z Li5, John R Koethe6, Karam Mounzer7, Jay R Kostman7, Qin Liu1, Luis J Montaner1, Mohamed Abdel-Mohsen8.   

Abstract

Lipids are biologically active molecules involved in a variety of cellular processes and immunological functions, including inflammation. It was recently shown that phospholipids and their derivatives, lysophospholipids, can reactivate latent (dormant) tumor cells, causing cancer recurrence. However, the potential link between lipids and HIV latency, persistence, and viral rebound after cessation of antiretroviral therapy (ART) has never been investigated. We explored the links between plasma lipids and the burden of HIV during ART. We profiled the circulating lipidome from plasma samples from 24 chronically HIV-infected individuals on suppressive ART who subsequently underwent an analytic treatment interruption (ATI) without concurrent immunotherapies. The pre-ATI viral burden was estimated as time-to-viral-rebound and viral load set points post-ATI. We found that higher pre-ATI levels of lysophospholipids, including the proinflammatory lysophosphatidylcholine, were associated with faster time-to-viral-rebound and higher viral set points upon ART cessation. Furthermore, higher pre-ATI levels of the proinflammatory by-product of intestinal lysophosphatidylcholine metabolism, trimethylamine-N-oxide (TMAO), were also linked to faster viral rebound post-ART. Finally, pre-ATI levels of several phosphatidylcholine species (lysophosphatidylcholine precursors) correlated strongly with higher pre-ATI levels of HIV DNA in peripheral CD4+ T cells. Our proof-of-concept data point to phospholipids and lysophospholipids as plausible proinflammatory contributors to HIV persistence and rapid post-ART HIV rebound. The potential interplay between phospholipid metabolism and both the establishment and maintenance of HIV latent reservoirs during and after ART warrants further investigation.IMPORTANCE The likelihood of HIV rebound after stopping antiretroviral therapy (ART) is a combination of the size of HIV reservoirs that persist despite ART and the host immunological and inflammatory factors that control these reservoirs. Therefore, there is a need to comprehensively understand these host factors to develop a strategy to cure HIV infection and prevent viral rebound post-ART. Lipids are important biologically active molecules that are known to mediate several cellular functions, including reactivating latent tumor cells; however, their role in HIV latency, persistence, and post-ART rebound has never been investigated. We observed significant links between higher levels of the proinflammatory lysophosphatidylcholine and its intestinal metabolic by-product, trimethylamine-N-oxide, and both faster time-to-viral-rebound and higher viral load set point post-ART. These data highlight the need for further studies to understand the potential contribution of phosphatidylcholine and lysophosphatidylcholine metabolism in shaping host immunological and inflammatory milieu during and after ART.
Copyright © 2021 Giron et al.

Entities:  

Keywords:  HIV; HIV persistence; TMAO; choline; lipids; lysophosphatidylcholine; lysophospholipid; phospholipid; viral rebound

Year:  2021        PMID: 33622719     DOI: 10.1128/mBio.03444-20

Source DB:  PubMed          Journal:  mBio            Impact factor:   7.867


  7 in total

1.  "We are looking at the future right now": community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States.

Authors:  Karine Dubé; John Kanazawa; Christopher Roebuck; Steven Johnson; William B Carter; Lynda Dee; Beth Peterson; Kenneth M Lynn; Linden Lalley-Chareczko; Emily Hiserodt; Sukyung Kim; Daniel Rosenbloom; Brad R Evans; Melanie Anderson; Daria J Hazuda; Lisa Shipley; Kevin Bateman; Bonnie J Howell; Karam Mounzer; Pablo Tebas; Luis J Montaner
Journal:  HIV Res Clin Pract       Date:  2022-03-29

Review 2.  Innate metabolic responses against viral infections.

Authors:  Clovis S Palmer
Journal:  Nat Metab       Date:  2022-10-20

3.  Preliminary Acceptability of a Home-Based Peripheral Blood Collection Device for Viral Load Testing in the Context of Analytical Treatment Interruptions in HIV Cure Trials: Results from a Nationwide Survey in the United States.

Authors:  Karine Dubé; Shadi Eskaf; Elizabeth Hastie; Harsh Agarwal; Laney Henley; Christopher Roebuck; William B Carter; Lynda Dee; Jeff Taylor; Derrick Mapp; Danielle M Campbell; Thomas J Villa; Beth Peterson; Kenneth M Lynn; Linden Lalley-Chareczko; Emily Hiserodt; Sukyung Kim; Daniel Rosenbloom; Brad R Evans; Melanie Anderson; Daria J Hazuda; Lisa Shipley; Kevin Bateman; Bonnie J Howell; Karam Mounzer; Pablo Tebas; Luis J Montaner
Journal:  J Pers Med       Date:  2022-02-07

4.  Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control.

Authors:  Jenifer Masip; Norma Rallón; Elena Yeregui; Montserrat Olona; Salvador Resino; José M Benito; Consuelo Viladés; Graciano García-Pardo; José Alcamí; Ezequiel Ruiz-Mateos; Frederic Gómez-Bertomeu; Montserrat Vargas; Marta Navarro; José A Oteo; Juan A Pineda; Anna Martí; Verónica Alba; Francesc Vidal; Joaquin Peraire; Anna Rull
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

Review 5.  The Role of Pannexin-1 Channels in HIV and NeuroHIV Pathogenesis.

Authors:  Cristian A Hernandez; Eugenin Eliseo
Journal:  Cells       Date:  2022-07-20       Impact factor: 7.666

6.  Mass spectrometry imaging identifies altered hepatic lipid signatures during experimental Leishmania donovani infection.

Authors:  Roel Tans; Shoumit Dey; Nidhi Sharma Dey; Jian-Hua Cao; Prasanjit S Paul; Grant Calder; Peter O'Toole; Paul M Kaye; Ron M A Heeren
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

7.  Participant experiences using novel home-based blood collection device for viral load testing in the HIV cure trials with analytical treatment interruptions.

Authors:  Karine Dubé; Harsh Agarwal; William B Carter; Lynda Dee; Jeff Taylor; Christopher Roebuck; Beth Peterson; Hursch Patel; Samuel Ndukwe; Kenneth M Lynn; Linden Lalley-Chareczko; Emily Hiserodt; Sukyung Kim; Daniel Rosenbloom; Brad R Evans; Melanie Anderson; Daria J Hazuda; Kevin Bateman; Bonnie J Howell; Livio Azzoni; Karam Mounzer; Pablo Tebas; Luis J Montaner
Journal:  HIV Res Clin Pract       Date:  2022-08-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.